Compare CarMax, Inc (KMX) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CarMax, Inc vs Medpace Holdings Inc — how do they compare? CarMax, Inc trades at $52.91 (market cap $7.64B), while Medpace Holdings Inc trades at $614.17 (market cap $16.82B). The key difference: Medpace Holdings Inc is far larger — about 2.2× CarMax, Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, CarMax, Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold CarMax, Inc for 49 Days and Medpace Holdings Inc for 14 Days on average.
| KMX | MEDP | |
|---|---|---|
Market Cap | $7.64B | $16.82B |
Volume | 3,610,116 | 223,093 |
Sector | Consumer Cyclical | Health |
52-Week High | $64.22 | $630.19 |
52-Week Low | $30.88 | $393.42 |
Typical Hold Time | 49 Days | 14 Days |
Enterprise Value | $25.34B | $16.44B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CarMax (KMX) trades at $52.82, down 0.86% today, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $1.16 beating estimates by 58%, driven by 19.5% revenue growth to $7.9 billion. Valuation metrics show a P/E of 25.37 and P/S of 0.28, while profitability remains modest with 1.06% net margin. Recent news highlights the company's 'Shift into GEAR' turnaround strategy showing early success.
KMX presents a mixed outlook with improving operational performance offset by high debt levels and competitive pressures. The consensus price target of $58.89 suggests 11% upside potential, but analysts remain cautious with 62% hold ratings. Key risks include cyclical auto market exposure and interest rate sensitivity, while catalysts include continued execution of the turnaround strategy and potential share buybacks.
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About CarMax, Inc
CarMax sells, finances, and services used and new cars through a chain of over 230 used retail stores. It was formed in 1993 as a unit of Circuit City and spun off into an independent company in late 2002. Used-vehicle sales typically account for about 83% of revenue and wholesale about 13%, with the remaining portion composed of extended service plans and repair. In fiscal 2022, the company retailed and wholesaled 924,338 and 706,212 used vehicles, respectively. CarMax is the largest used-vehicle retailer in the U.S. but still estimates that it has only about 4% U.S. market share of vehicles 0-10 years old in 2021. It seeks over 5% share by the end of calendar 2025 and revenue between $33 billion to $45 billion by fiscal 2026. CarMax is based in Richmond, Virginia.
Read more on KMX →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
